** Drug and Medical device maker Johnson & Johnson JNJ.N beat Q1 estimates on strong sales of its cancer treatments, including multiple myeloma medicine Darzalex
** Median PT of 26 brokerages covering the stock is $169.50 - LSEG data
LOOKS SOMEWHAT IMMUNE DESPITE TARIFFS
** J.P.Morgan ("neutral," PT: $185) expects co to maintain steady growth, despite concerns about litigation and tariffs impacting sales in China
** RBC ("outperform," PT: $181) believes co is well-positioned for growth in MedTech due to its strong portfolio and innovation, particularly in heart failure treatments, electrophysiology, and surgical robotics
** TD Cowen ("buy," PT: $185) believes co can manage $400 mln tariff costs and still meet its 2025 earnings goals, which mainly affects its MedTech products shipped from the U.S. to China
** Morgan Stanley ("equal-weight," PT: $169) see JNJ's strategic investments as a positive move despite tariff impact
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。